Liu Zhu-Qing, Fang Jue-Min, Xiao Yuan-Yuan, Zhao Yu, Cui Ran, Hu Fei, Xu Qing
Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Int J Clin Exp Med. 2015 Feb 15;8(2):2289-98. eCollection 2015.
The objective of this study was to perform a meta-analysis and literature review on the predictive role of vascular endothelial growth factor (VEGF) in prostate cancer. A detailed literature search was performed using PubMed and Embase databases for related research publications written in English. Methodological quality of the studies was also evaluated. Data was collected from studies comparing overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), biomedical failure (BF) and cancer-specific survival (CSS) in patients with elevated VEGF levels and those having lower levels. The hazard ratio (HR) and its 95% confidence interval (CI) were used to assess the strength of associations. A total of 12 studies (n = 1,737) were included in this meta-analysis (4 for OS, 3 for CSS, 2 for DFS, 4 for BF, and 4 for PFS). For OS, DFS and PFS, the pooled HR for VEGF was not statistically significant at 1.30 (95% CI, 0.74-2.29), 0.80 (95% CI, 0.57-1.13) and 1.04 (95% CI, 0.93-1.16), respectively. However, for CSS and BF, the pooled HR was 2.32 (95% CI, 1.20-4.46) and 1.30 (95% CI, 1.06-1.59), respectively. Our results demonstrate that VEGF may have a critical prognostic value in patients with prostatic cancer.
本研究的目的是对血管内皮生长因子（VEGF）在前列腺癌中的预测作用进行荟萃分析和文献综述。使用PubMed和Embase数据库对用英文撰写的相关研究出版物进行了详细的文献检索。还评估了这些研究的方法学质量。数据收集自比较VEGF水平升高和降低的患者的总生存期（OS）、无进展生存期（PFS）、无病生存期（DFS）、生物医学失败（BF）和癌症特异性生存期（CSS）的研究。风险比（HR）及其95%置信区间（CI）用于评估关联强度。本荟萃分析共纳入12项研究（n = 1737）（OS相关4项，CSS相关3项，DFS相关2项，BF相关4项，PFS相关4项）。对于OS、DFS和PFS，VEGF的合并HR分别为1.30（95%CI，0.74 - 2.29）、0.80（95%CI，0.57 - 1.13）和1.04（95%CI，0.93 - 1.16），差异无统计学意义。然而，对于CSS和BF，合并HR分别为2.32（95%CI，1.20 - 4.46）和1.30（95%CI，1.06 - 1.59）。我们的结果表明，VEGF可能对前列腺癌患者具有关键的预后价值。
